Diligence memo · auto-generated · as of July 2, 2026
BeyondSpring Inc.
BeyondSpring Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
BeyondSpring Inc. operates in Biotechnology, based in New York.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BeyondSpring Inc. has raised $7.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.2M on 2017-03-14.
Most recent recorded round closed around 2017-03-14.
Valuation (modeled)modeled
Provath models BeyondSpring Inc. at approximately $261M (range $7.9M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.24× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era. Within the normal band (124% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 9.3 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 50% of Biotechnology peers (4291 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Cynvec LLC, Anthera Pharmaceuticals Inc, Bio-Dent, LTD. LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.